Preparation method of baricitinib

Preparation of baritinib by the closure reaction method solves the problems of long reaction steps, high reagent costs and harsh reaction conditions in the prior art, and achieves efficient and safe baritinib synthesis, providing easy-to-get raw materials and Mild reaction conditions provide a reliable basis for industrial production.

CN119019409APending Publication Date: 2024-11-26SUZHOU YUANXIN TECH IND PARK CO LTD

Patent Information

Application Number
CN202411139798.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing baritinib synthesis method has long reaction steps, high reagent costs, requires precious metal catalysis, harsh reaction conditions and complex post-treatment.

Method used

The ring-off reaction method was used to prepare baritinib, and the reaction conditions were optimized by the ring-off reaction of compound 3 and 2-(1-(ethylsulfonyl)-3-hydrazineazetidone-3-yl)acetonitrile. The solvent used is carried out in a third solvent of 0 to 100°C, including water, dichloromethane, tetrahydrofuran, acetonitrile, etc., and the reaction temperature is 20 to 50°C, and the molar ratio of compound 3 to reactant is 1:1 to 3.

Benefits of technology

The preparation of baritinib with high reaction yield and high product purity is achieved. The raw materials are easily obtained, the reaction conditions are mild, and the operation is easy to control, which avoids the use of toxic substances and lays the foundation for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019409A_ABST
    Figure CN119019409A_ABST
Patent Text Reader

Abstract

The invention relates to a preparation method of baricitinib. The preparation method comprises the following steps: carrying out ring closing reaction on a compound 3 and 2-(1-(ethylsulfonyl)-3-hydrazino azetidine-3-yl) acetonitrile to obtain baricitinib, the chemical general formula of the compound 3 is # imgabs0, in the formula, R1 and R2 are independently selected from C1-C4 alkyl, 3-6-membered cycloalkyl, heterocyclic radical or derivatives thereof, or R1, R2 and correspondingly connected N atoms form 4-6-membered heterocyclic radical; r3 and R4 are independently selected from C1-C4 alkyl groups, 3-6-membered cycloalkyl groups, heterocyclic groups or derivatives thereof, or R3, R4 and correspondingly connected N atoms form 4-6-membered heterocyclic groups; r1, R2, R3 and R4 are not methyl at the same time. The final product is obtained through the ring closing reaction, and the product with high reaction yield and high product purity can be obtained.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of organic synthesis and relates to a method for synthesizing a drug, in particular to a method for preparing baricitinib. Background Art

[0002] The chemical structure of Baricitinib is as follows: Its chemical name is: 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidinylacetonitrile; it is a selective JAK1 / JAK2 inhibitor jointly developed by Eli Lilly and Company and Incyte Corp. It can inhibit the intracellular signal transduction of multiple inflammatory cytokines such as IL-6 and IL-23, and is used to treat autoimmune diseases and related inflammations, such as rheumatoid arthritis.

[0003] At present, many methods for synthesizing baricitinib have been disclosed, such as those disclosed in patent documents WO2021053690, WO2016205487, WO2009114512, US20090233903, CN106496195A, etc. The synthetic routes recorded in the above patent documents have the disadvantages of long reaction steps, high reagent cost, need for precious metal catalysis, harsh reaction conditions, and complex post-treatment (column chromatography is required). Summary of the invention

[0004] The object of the present invention is to provide a method for preparing baricitinib with readily available reaction raw materials, mild reaction conditions, easy operation control, and safety and reliability, so as to solve the problems raised in the above-mentioned background technology.

[0005] To achieve the above object, the present invention provides the following technical solution: a method for preparing baricitinib, comprising the following steps:

[0006] Compound 3 is subjected to a ring-closing reaction with 2-(1-(ethylsulfonyl)-3-hydrazinoazetidin-3-yl)acetonitrile to obtain baricitinib;

[0007] The general chemical formula of compound 3 is In the formula, R1 and R2 are independently selected from C1-C4 alkyl, 3-6-membered cycloalkyl, heterocyclic group or derivatives thereof, or R1, R2 and the corresponding connected N atom form a 4-6-membered heterocyclic group; R3 and R4 are independently selected from C1-C4 alkyl, 3-6-membered cycloalkyl, heterocyclic group or derivatives thereof, or R3, R4 and the corresponding connected N atom form a 4-6-membered heterocyclic group; and R1, R2, R3 and R4 are not methyl groups at the same time.

[0008] Optimally, the ring-closure reaction is carried out in a third solvent at a reaction temperature of 0 to 100° C., and the third solvent is a mixture of one or more selected from water, dichloromethane, tetrahydrofuran, acetonitrile, acetone, methanol, ethanol, isopropanol, N,N-dimethylformamide and toluene.

[0009] Furthermore, the molar ratio of the compound 3 to the 2-(1-(ethylsulfonyl)-3-hydrazinoazetidine-3-yl)acetonitrile is 1:1-3.

[0010] Furthermore, the reaction temperature of the ring-closure reaction is 20-50° C., and the third solvent is ethanol.

[0011] Optimally, the compound 3 is selected from any one of the following chemical structural formulas:

[0012]

[0013] Compared with the prior art, the beneficial effects of the present invention are as follows: the preparation method of baricitinib of the present invention obtains the final product by adopting a ring-closing reaction, and the raw materials of the ring-closing reaction can be obtained by existing methylation reactions, formylation reactions and the like, and a product with high reaction yield and high product purity can be obtained; moreover, the raw materials for the synthesis reaction are easily available, the reaction conditions are mild, the operation is easy to control, the raw materials are safe and reliable, and the use of toxic substances is avoided, which can lay a foundation for later industrial scale-up production. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 is a process flow chart of the preparation method of baricitinib of the present invention;

[0015] Figure 2 is the NMR spectrum of compound 2;

[0016] Figure 3 is the NMR spectrum of compound 3-1;

[0017] Figure 4 is the NMR spectrum of compound 3-2;

[0018] Figure 5 This is the NMR spectrum of baricitinib. DETAILED DESCRIPTION

[0019] The preparation method of baricitinib of the present invention comprises the following steps: subjecting compound 3 to a ring-closing reaction with 2-(1-(ethylsulfonyl)-3-hydrazinoazetidine-3-yl)acetonitrile to obtain baricitinib;

[0020] The general chemical formula of compound 3 is In the formula, R1 and R2 are independently selected from C1-C4 alkyl, 3-6-membered cycloalkyl, heterocyclic group or derivatives thereof, or R1, R2 and corresponding connected N atoms form 4-6-membered heterocyclic group; R3 and R4 are independently selected from C1-C4 alkyl, 3-6-membered cycloalkyl, heterocyclic group or derivatives thereof, or R3, R4 and corresponding connected N atoms form 4-6-membered heterocyclic group; and R1, R2, R3 and R4 are not methyl at the same time. The final product is obtained by adopting the ring-closing reaction, and the raw materials of the ring-closing reaction can be obtained by existing methylation reaction, formylation reaction and other reactions, so that products with high reaction yield and high product purity can be obtained; and the raw materials of the synthesis reaction are easy to obtain, the reaction conditions are mild, the operation is easy to control, the raw materials are safe and reliable, and the use of toxic substances is avoided, which can lay the foundation for later industrialized scale-up production.

[0021] The ring-closing reaction is preferably carried out in a third solvent, and the reaction temperature is preferably 0 to 100°C. The third solvent is preferably a mixture of one or more selected from water, dichloromethane, tetrahydrofuran, acetonitrile, acetone, methanol, ethanol, isopropanol, N,N-dimethylformamide and toluene. The molar ratio of the compound 3 to the 2-(1-(ethylsulfonyl)-3-hydrazinoazetidine-3-yl)acetonitrile is preferably 1:1 to 3. The reaction temperature of the ring-closing reaction is more preferably 20 to 50°C, and the third solvent is more preferably ethanol.

[0022] The above compound 3 is any one selected from the following chemical structural formulas:

[0023]

[0024]

[0025] The above compound 3 is prepared by the following steps: (1) subjecting compound 1 to a methylation reaction with a methyl Grignard reagent to obtain compound 2; the chemical formula of compound 1 is The chemical formula of compound 2 is (2) Compound 2 is subjected to formylation reaction with Vilsmeier's reagent to obtain compound 3.

[0026] In step (1), the methyl Grignard reagent is a mixture of one or more selected from methylmagnesium chloride, methylmagnesium bromide and methylmagnesium iodide, preferably methylmagnesium chloride. The methylation reaction is carried out in a first solvent, which is a mixture of one or more selected from tetrahydrofuran, 2-methyltetrahydrofuran, N,N-dimethylformamide, dioxane, ethyl acetate and toluene; preferably tetrahydrofuran. In step (1), the methylation reaction is preferably carried out in the presence of a ferric iron reagent or a palladium reagent; the ferric iron reagent is a mixture of one or more selected from ferric chloride, triacetyl acetonate iron, ferric acetate, ferric nitrate and ferric sulfate, preferably triacetyl acetonate iron; the palladium reagent is a mixture of one or more selected from [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex. In step (1), the reaction temperature of the methylation reaction is 0 to 80°C, preferably 10 to 20°C. The molar ratio of the compound 1 to the methyl Grignard reagent is 1:1-5, preferably 1:1-3, more preferably 1:2.5. The molar ratio of the compound 1 to the ferric iron reagent or the palladium reagent is 1:0.01-0.3, preferably 1:0.01-0.05, most preferably 1:0.03.

[0027] In step (2), the C1-C4 alkyl, 3-6 membered cycloalkyl, and heterocyclic group in R1, R2, R3, and R4 are independently substituted by 1-3 substituents selected from alkyl, hydroxy, halogen, cyano, amino, or alkoxy. The formylation reaction is carried out in a second solvent, the second solvent is a mixture of one or more selected from dichloromethane, tetrahydrofuran, acetonitrile, N,N-dimethylformamide and toluene, preferably acetonitrile; the Vilsmeier reagent is formed by a chlorination reagent and a formylation reagent, the chlorination reagent is a mixture of one or more selected from oxalyl chloride, phosphorus oxychloride, triphosgene, thionyl chloride, sulfuryl chloride and phosphorus oxychloride, preferably oxalyl chloride or phosphorus oxychloride; the formylation reagent is one or more selected from N,N-diethylformamide, N,N-dibutylformamide, N-ethyl-N-methyl-formamide, N-formylmorpholine, N-formylpiperidine and 1-formylpyrrolidine, preferably N,N-diethylformamide or N,N-dibutylformamide. In step (b), the reaction temperature for forming the Vilsmeier reagent is -10 to 10°C; the temperature for the reaction of the compound 2 with the Vilsmeier reagent is -10 to 90°C, preferably 50 to 80°C. The molar ratio of the compound 2 to the chlorination reagent and the formylation reagent is 1:1-5:2-15, preferably 1:1-3:3-13, and optimally 1:2.25:12.9.

[0028] The method of the present invention is described below by means of specific examples. It should be understood that these examples are used to illustrate the basic principles, main features and advantages of the present invention, and the present invention is not limited to the scope of the following examples; the implementation conditions adopted in the examples can be further adjusted according to specific requirements, and the implementation conditions not specified are usually the conditions in routine experiments.

[0029] In the following embodiments 1 H NMR spectra were measured using a Bruker instrument (400 MHz), and chemical shifts were expressed in ppm using tetramethylsilane as an internal standard (0.00 ppm). 1 H NMR notation: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, dd = doublet of doublet, dt = doublet of triplet. Coupling constants, when provided, are in Hz. Mass spectra were obtained using LC / MS, using ESI as the ionization method.

[0030] High performance liquid chromatograph model: Agilent 1260, Thermo Fisher U3000; chromatographic column model: Waters xbrigeC18 (4.6*150mm, 3.5μm); mobile phase: A: CAN, B: Water (0.1% H3PO4); flow rate: 1.0mL / min; gradient: 5% Afor 1min, increase to 20% A within 4min, increase to 80% Awithin 8min, 80% Afor2min, back to 5% Awithin 0.1min; wavelength: 220nm; column oven: 35℃. TLC: thin layer chromatography. Thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) uses a specification of 0.2mm-0.3mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm-0.5mm. Column chromatography generally uses Yantai Huanghai Silica Gel 200-300 mesh silica gel as the carrier.

[0031] In the following examples, unless otherwise specified, all temperatures are in degrees Celsius. Unless otherwise specified, various starting materials and reagents are commercially available or synthesized according to known methods. Commercially available materials and reagents are used directly without further purification. Unless otherwise specified, commercial manufacturers include but are not limited to Sinopharm Group, J&K Technology Co., Ltd., TCI (Shanghai) Chemical Industry Development Co., Ltd., Shanghai Bid Pharmaceutical Technology Co., Ltd. and Shanghai Myrel Chemical Technology Co., Ltd.

[0032] Unless otherwise specified in the examples, the solution in the reaction refers to an aqueous solution. Unless otherwise specified in the examples, the reaction temperature is room temperature (20°C-30°C). The reaction progress in the examples is monitored by thin layer chromatography (TLC), and the developing solvent used in the reaction, the eluent system of column chromatography used for purifying the compound or the developing solvent system of thin layer chromatography includes: A: petroleum ether and ethyl acetate system; B: dichloromethane and methanol system; C: n-hexane: ethyl acetate; wherein the volume ratio of the solvent varies according to the polarity of the compound, and a small amount of acidic or alkaline reagents, such as acetic acid or triethylamine, can also be added for adjustment.

[0033] The preferred embodiments of the present invention will be described in detail below.

[0034] Example 1

[0035] This embodiment provides a method for preparing baricitinib, comprising the following steps:

[0036] (a) Synthesis of Compound 2 (4-methyl-7H-pyrrolo[2,3-D]pyrimidine)

[0037]

[0038] Compound 1 (4-chloro-1H-pyrrolo[2,3-c]pyridine, 30.00 g, 0.20 mol) was dissolved in THF (300 mL), triacetylacetonate iron (6.97 g, 19.51 mmol) was added, methylmagnesium chloride (167 mL, 0.50 mol) was added dropwise, the temperature was controlled at -10-0 °C, the temperature was raised to 15-20 °C for reaction for 3 hours, and the reaction was complete by TLC detection. The reaction solution was cooled to -10-0 °C, and an aqueous solution of ammonium chloride (12.00 g, 450 mL) was added dropwise to quench, the temperature was controlled at 0-20 °C, stirred for 10 minutes, separated, the aqueous phase was extracted with EA, the organic phase was washed with saturated sodium chloride, and the organic phase was concentrated to obtain a brown solid crude product, which was beaten with ethyl acetate to obtain an off-white solid compound 2 (18.15 g, yield 69.8%), LC-MS: m / z=134.2[M+H] + (98.56%purity, 254nm), 1 H NMR (400MHz, DMSO-d6) δ12.01(s,1H),8.61(s,1H),7.48(dd,J=2.8Hz,3.2Hz,1H),6.63(dd,J=1.6Hz,3.6Hz,1H),6.64-6.63(m,1H),2.65(s,3H), such as Figure 2 shown.

[0039] (b) Synthesis of Compound 3-1 ((E)-N-(3-(diethylamino)-2-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)allylidene)-N-ethylethylammonium chloride)

[0040]

[0041] Oxalyl chloride (42.95 g, 338.35 mmol) was dissolved in anhydrous acetonitrile (100 ml), cooled to 0 ° C, and diethylformamide (176.33 g, 1.74 mol) was added dropwise. The temperature was controlled at 0-10 ° C during the process, and the reaction was kept warm for 0.5 hours. Compound 2 (18.00 g, 135.19 mmol) was added, and the reaction was carried out at room temperature for 0.5 hours and at 80 ° C for 2 hours. TLC detected that the raw material reaction was complete. Tetrahydrofuran (100 mL) was added to the reaction solution, stirred at room temperature for 10 minutes, filtered, and the filter cake was washed with tetrahydrofuran (20 mL) and dried to obtain an off-white solid compound 3-1 (47.32 g, yield 94%). LC-MS: m / z=301.2 [M+H] + (98.74%purity, 254nm), 1 H NMR(400MHz,DMSO-d6)δ13.03(s,1H),8.96(s,1H),8.26(s,2H),7.83-7.82(m,1H),6.6 4-6.63(m,1H),3.53(q,J=7.2Hz,4H),2.74(s,4H),1.26(t,J=7.2Hz,6H),0.61(s,6H), such as Figure 3 shown.

[0042] (c) Synthesis of Compound 4 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidinylacetonitrile

[0043]

[0044] Compound 3-1 (8.69 g, 23.31 mmol) was dissolved in ethanol (45 ml), 2-(1-(ethylsulfonyl)-3-hydrazinoazetidine-3-yl)acetonitrile (5.60 g, 25.64 mmol) was added, and the mixture was reacted at room temperature for 6 hours. The reaction was complete by TLC. A large solid was precipitated from the reaction solution, and n-heptane (22 mL) was added. The mixture was stirred at room temperature for 1 hour, filtered, and the filter cake was rinsed with n-heptane (10 mL) and dried at 45°C to obtain an off-white solid 4 (8.31 g, 96.0% yield). LC-MS: m / z=372.1[M+H] + (99.87%purity, 254nm), 1HNMR (400MHz, DMSO-d6) δ12.13(s,1H),8.93(s,1H),8.71(s,1H),8.48(s,1H),7.62(d,J=3.2Hz,1H),7.08(d,J=3.6Hz, 1H), 4.61 (d, J = 9.2Hz, 2H), 4.25 (d, J = 12.8Hz, 2H), 3.70 (s, 2H), 3.24 (q, J = 7.2Hz, 2H), 1.23 (t, J = 7.2Hz, 14.8Hz, 3H), such as Figure 5 shown.

[0045] Example 2

[0046] This example provides a method for preparing baricitinib, which is basically the same as that in Example 1, except that:

[0047] (b) Synthesis of Compound 3-2 ((E)-N-butyl-N-(3-(dibutylamino)-2-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)allyl)butan-1-ammonium chloride)

[0048]

[0049] Oxalyl chloride (2.14 g, 16.90 mmol) was dissolved in anhydrous acetonitrile (10 ml), cooled to 0°C, and di-n-butylformamide (15.24 g, 96.88 mmol) was added dropwise. The temperature was controlled at 0-10°C during the process, and the reaction was kept warm for 0.5 hours. Compound 2 (1.00 g, 7.51 mmol) was added, and the reaction was carried out at room temperature for 0.5 hours and at 80°C for 2 hours. The reaction of the raw materials was complete by TLC detection. Tetrahydrofuran (10 mL) was added to the reaction solution, stirred at room temperature for 10 minutes, filtered, and the filter cake was washed with tetrahydrofuran (2 mL) and dried to obtain an off-white solid compound 3-2 (3.38 g, yield 93.0%). LC-MS: m / z=413.4[M+H] + (98.53%purity, 254nm), 1 H NMR (400MHz, DMSO-d6) δ12.82(s,1H),8.93(s,1H),8.19(s,2H),7.82-7.81(m,1H),6.54(d,J=2.0Hz,1H),3.46(t,J=7.2H z,4H),2.59(s,4H),1.65-1.58(m,4H),1.35-1.23(m,6H),0.93(t,J=7.6Hz,6H),0.77(s,2H),0.38(s,8H),0.22(s,2H), such as Figure 4 shown.

[0050] (c) Synthesis of Compound 4 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidinylacetonitrile

[0051]

[0052] Compound 3-2 (3.38 g, 6.98 mmol) was dissolved in ethanol (15 ml), 2-(1-(ethylsulfonyl)-3-hydrazinoazetidine-3-yl)acetonitrile (1.67 g, 7.67 mmol) was added, and the mixture was reacted at room temperature for 6 hours. The reaction was complete by TLC. A large solid was precipitated from the reaction solution, and n-heptane (8 mL) was added. The mixture was stirred at room temperature for 1 hour, filtered, and the filter cake was washed with n-heptane (2 mL) and dried at 45°C to obtain an off-white solid 4 (2.48 g, 95.8% yield). LC-MS: m / z=372.1[M+H] + (99.81% purity, 254nm).

[0053] Example 3

[0054] This example provides a method for preparing baricitinib, which is basically the same as that in Example 1, except that:

[0055] (b) Synthesis of Compound 3-3 ((E)-4-(3-morpholinyl-2-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)allyl)morpholine-4-chloroium salt)

[0056]

[0057] Oxalyl chloride (2.14 g, 16.90 mmol) was dissolved in anhydrous acetonitrile (10 ml), cooled to 0°C, 4-formylmorpholine (11.15 g, 96.88 mmol) was added dropwise, the temperature was controlled at 0-10°C, and the reaction was kept warm for 0.5 hours. Compound 2 (1.00 g, 7.51 mmol) was added, and the reaction was carried out at room temperature for 0.5 hours and at 80°C for 2 hours. The reaction of the raw materials was complete by TLC detection. Tetrahydrofuran (10 mL) was added to the reaction solution, stirred at room temperature for 10 minutes, filtered, the filter cake was rinsed with tetrahydrofuran (2 mL), and dried to obtain an off-white solid compound 3-3 (2.79 g, yield 92.8%). LC-MS: m / z=329.2[M+H] + .

[0058] (c) Synthesis of Compound 4 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidinylacetonitrile

[0059]

[0060] Compound 3-3 (2.79 g, 6.97 mmol) was dissolved in ethanol (15 ml), 2-(1-(ethylsulfonyl)-3-hydrazinoazetidine-3-yl)acetonitrile (1.67 g, 7.67 mmol) was added, and the mixture was reacted at room temperature for 6 hours. The reaction was complete by TLC. A large solid was precipitated from the reaction solution, and n-heptane (8 mL) was added. The mixture was stirred at room temperature for 1 hour, filtered, and the filter cake was rinsed with n-heptane (2 mL) and dried at 45°C to obtain an off-white solid 4 (2.08 g, 80.2% yield). LC-MS: m / z=372.1[M+H] + (99.92% purity, 254nm).

[0061] Example 4

[0062] This example provides a method for preparing baricitinib, which is basically the same as that in Example 1, except that:

[0063] (b) Synthesis of Compound 3-4 ((E)-1-(3-(piperidin-1-yl)-2-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)allylidene)piperidin-1-chloroium salt 3-4)

[0064]

[0065] Oxalyl chloride (2.14 g, 16.90 mmol) was dissolved in anhydrous acetonitrile (10 ml), cooled to 0°C, and N-formylpiperidine (10.96 g, 96.88 mmol) was added dropwise. The temperature was controlled at 0-10°C during the process, and the reaction was kept warm for 0.5 hours. Compound 2 (1.00 g, 7.51 mmol) was added, and the reaction was carried out at room temperature for 0.5 hours and at 80°C for 2 hours. The reaction of the raw materials was complete by TLC detection. Tetrahydrofuran (10 mL) was added to the reaction solution, and the mixture was stirred at room temperature for 10 minutes, filtered, and the filter cake was rinsed with tetrahydrofuran (2 mL) and dried to obtain an off-white solid compound 3-4 (2.77 g, yield 93.1%). LC-MS: m / z=325.2[M+H] + .

[0066] (c) Synthesis of Compound 4 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidinylacetonitrile

[0067]

[0068] Compound 3-4 (2.77 g, 6.99 mmol) was dissolved in ethanol (15 ml), and 2-(1-(ethylsulfonyl)-3-hydrazinoazetidine-3-yl)acetonitrile (1.68 g, 7.69 mmol) was added. The mixture was reacted at room temperature for 6 hours. TLC detected that the reaction was complete. A large solid was precipitated from the reaction solution. n-heptane (8 mL) was added, stirred at room temperature for 1 hour, filtered, and the filter cake was rinsed with n-heptane (2 mL) and dried at 45°C to obtain an off-white solid 4 (1.92 g, 74.1% yield). LC-MS: m / z=372.1[M+H] + (99.68% purity, 254nm).

[0069] Example 5

[0070] This example provides a method for preparing baricitinib, which is basically the same as that in Example 1, except that:

[0071] (b) Synthesis of Compound 3-5 ((E)-1-(3-(pyrrolidin-1-yl)-2-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)allyl)pyrrolidine-1-chloroium salt)

[0072]

[0073] Oxalyl chloride (2.14 g, 16.90 mmol) was dissolved in anhydrous acetonitrile (10 ml), cooled to 0°C, and N-formylpiperidine (9.60 g, 96.88 mmol) was added dropwise. The temperature was controlled at 0-10°C during the process, and the reaction was kept warm for 0.5 hours. Compound 2 (1.00 g, 7.51 mmol) was added, and the reaction was carried out at room temperature for 0.5 hours, and at 80°C for 2 hours. The reaction of the raw materials was complete by TLC detection. Tetrahydrofuran (10 mL) was added to the reaction solution, stirred at room temperature for 10 minutes, filtered, and the filter cake was rinsed with tetrahydrofuran (2 mL) and dried to obtain an off-white solid compound 3-5 (2.51 g, yield 92.6%). LC-MS: m / z=297.2[M+H] + .

[0074] (c) Synthesis of Compound 4 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidinylacetonitrile

[0075]

[0076] Compound 3-5 (2.51 g, 6.81 mmol) was dissolved in ethanol (15 ml), 2-(1-(ethylsulfonyl)-3-hydrazinoazetidine-3-yl)acetonitrile (1.64 g, 7.50 mmol) was added, and the mixture was reacted at room temperature for 6 hours. TLC detected that the reaction was complete. A large solid precipitated from the reaction solution, and n-heptane (8 mL) was added. The mixture was stirred at room temperature for 1 hour, filtered, rinsed with n-heptane (2 mL), and dried at 45°C to obtain an off-white solid 4 (1.78 g, 70.3% yield). LC-MS: m / z=372.1[M+H] + (99.73% purity, 254nm).

[0077] Comparative Example 1

[0078] This example provides a method for preparing baricitinib, which is basically the same as that in Example 1, except that in step (a), ferric triacetylacetonate is not used, resulting in that compound 1 does not react with methylmagnesium chloride.

[0079] Comparative Example 2

[0080] This example provides a preparation method of baricitinib, which is basically the same as that in Example 2, except that: in step (b), oxalyl chloride (4.30g, 33.83mmol) is dissolved in anhydrous acetonitrile (10ml), cooled to 0°C, and diethylformamide (27.34g, 0.27mol, 20eq) is added dropwise, the process temperature is controlled at 0-10°C, and the reaction is kept warm for 0.5 hours. Add compound 2 (1.80g, 13.52mmol), react at room temperature for 0.5 hours, react at 80°C for 2 hours, and TLC detects that the raw material reacts completely. Add tetrahydrofuran (100mL) to the reaction solution, stir at room temperature for 10 minutes, filter, wash the filter cake with tetrahydrofuran (20mL), and dry to obtain an off-white solid compound 3-1 (4.23g, yield 84.0%). LC-MS: m / z=301.2[M+H] + (98.84% purity, 254nm).

[0081] Comparative Example 3

[0082] This example provides a preparation method of baricitinib, which is basically the same as that in Example 1, except that: in step (c), compound 3-1 (10.00 g, 26.86 mmol) is dissolved in ethanol (50 ml), 2-(1-(ethylsulfonyl)-3-hydrazinoazetidine-3-yl)acetonitrile (2.93 g, 13.43 mmol, 0.5 eq) is added, and the reaction is carried out at room temperature for 6 hours. The reaction is complete after TLC detection. A large solid precipitates from the reaction solution, n-heptane (25 mL) is added, stirred at room temperature for 1 hour, filtered, rinsed with n-heptane (10 mL), and dried at 45°C to obtain an off-white solid 4 (4.30 g, 43.1% yield). LC-MS: m / z=372.1[M+H] + (99.73% purity, 254nm).

[0083] Comparative Example 4

[0084] This example provides a method for preparing baricitinib, which is basically the same as that in Example 1, except that: in step (c), compound 3-1 (10.00 g, 26.86 mmol) is dissolved in ethanol (50 ml), 2-(1-(ethylsulfonyl)-3-hydrazinoazetidine-3-yl)acetonitrile (11.72 g, 53.71 mmol, 2.0 eq) is added, and the reaction is carried out at room temperature for 6 hours. The reaction is complete after TLC detection. A large solid is precipitated from the reaction solution, and n-heptane (25 mL) is added, stirred at room temperature for 1 hour, filtered, rinsed with n-heptane (10 mL), and dried at 45°C to obtain an off-white solid 4 (8.62 g, 86.4% yield). LC-MS: m / z=372.1[M+H] + (99.73% purity, 254nm).

[0085] The above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing baricitinib, characterized in that: The following steps are involved: Compound 3 is subjected to a ring-closing reaction with 2-(1-(ethylsulfonyl)-3-hydrazinoazetidin-3-yl)acetonitrile to obtain baricitinib; The general chemical formula of compound 3 is In the formula, R1 and R2 are independently selected from C1-C4 alkyl, 3-6-membered cycloalkyl, heterocyclic group or derivatives thereof, or R1, R2 and the corresponding connected N atom form a 4-6-membered heterocyclic group; R3 and R4 are independently selected from C1-C4 alkyl, 3-6-membered cycloalkyl, heterocyclic group or derivatives thereof, or R3, R4 and the corresponding connected N atom form a 4-6-membered heterocyclic group; and R1, R2, R3 and R4 are not methyl groups at the same time.

2. The method for preparing baricitinib according to claim 1, characterized in that: The ring-closing reaction is carried out in a third solvent at a reaction temperature of 0 to 100° C. The third solvent is a mixture of one or more selected from water, dichloromethane, tetrahydrofuran, acetonitrile, acetone, methanol, ethanol, isopropanol, N,N-dimethylformamide and toluene.

3. The method for preparing baricitinib according to claim 1 or 2, characterized in that: The molar ratio of the compound 3 to the 2-(1-(ethylsulfonyl)-3-hydrazinoazetidin-3-yl)acetonitrile is 1:1-3.

4. The method for preparing baricitinib according to claim 2, characterized in that: The reaction temperature of the ring-closure reaction is 20-50° C., and the third solvent is ethanol.

5. The method for preparing baricitinib according to claim 1, characterized in that: The compound 3 is selected from any one of the following chemical structural formulas:

Citation Information

Patent Citations

  • Novel synthetic method for baricitinib and intermediate thereof

    CN106496195A

  • Azetidine and cyclobutane derivatives as JAK inhibitors

    US20090233903A1

  • Azetidine and cyclobutane derivatives as JAK inhibitors

    WO2009114512A1

  • PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF {1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]AZETIDIN-3-YL}ACETONITRILE

    WO2016205487A1

  • An improved process for the preparation of baricitinib

    WO2021053690A1

Cited By

  • Preparation method for JAK inhibitor, and intermediate thereof

    WO2025252157A1